Edge­wise's heart drug shows promise in Phase 2 tri­al

Edge­wise Ther­a­peu­tics’ car­diac sar­com­ere mod­u­la­tor has passed a mid-stage test in pa­tients with a ge­net­ic heart mus­cle dis­ease.

The biotech’s EDG-7500 pro­duced “mean­ing­ful” re­duc­tions in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER